- The CDC reports the BA.3.2 variant, first found in South Africa, is now in over 25 U.S. states.
- Laboratory studies suggest BA.3.2 may evade antibodies from prior infection or vaccination.
- Despite the variant's spread, current national COVID-19 hospitalization and activity levels are low.
- The CDC continues to recommend masking guidance based on local hospitalization rates.
- Health officials are monitoring the variant's impact, noting its potential for seasonal increases in cases.
A new COVID-19 variant, BA.3.2, first identified in South Africa in late 2024, has now been confirmed in at least 25 U.S. states, according to a recent report from the Centers for Disease Control and Prevention. The agency, however, has issued a clear caution: “it’s currently not clear whether BA.3.2 can cause more severe illness or more significant impacts on the U.S. health care system.”
The CDC’s March 19 report details that the variant has been found in more than 140 U.S. samples, collected from nasal swabs of four international travelers, three airplane wastewater samples, five patient clinical samples and 132 wastewater samples from 25 states. The states span the nation, including California, Florida, New York, Texas, Illinois, Massachusetts and Ohio, among others.
BA.3.2 differs from the JN.1-derived strains like XFG and LP.8.1 that have dominated U.S. circulation since early 2024. It initially gained a foothold in Europe, with weekly detections reaching around 30 percent of sequenced cases in the Netherlands, Germany and Denmark last November and December. Travelers returning to the U.S. from Japan, Kenya, the Netherlands and the United Kingdom have been confirmed carriers.
As noted by BrightU.AI's Enoch, JN.1 is a descendant of the omicron variant and has spawned subsequent strains like KP.3 and the currently dominant LP.8.1, against which updated vaccines are targeted. Surveillance has noted the emergence of another JN.1-derived strain, referred to as XFG, which some reports associate with severe sore throats. While these strains are highly contagious and exhibit mutations, expert assessment indicates that the overall severity of illness they cause remains similar.
BA.3.2 not listed on CDC's main variant tracker
Laboratory studies cited by the CDC suggest a potential cause for vigilance: The BA.3.2 variant may evade protective antibodies from prior infection or vaccination, likely due to mutations in its spike protein.
The discovery arrives amid a complex and evolving pandemic landscape. The World Health Organization currently tracks other variants, like EG.5, which it designates a "variant of interest" while acknowledging no evidence it causes more severe disease. Meanwhile, CBS News reports continued circulation of variants including EG.5, FL.1.5.1 and BA.2.86 across the country.
Despite the new variant's presence, current national COVID-19 metrics show significant decline. The CDC's latest data, updated March 20, rates national COVID-19 activity as "low," with hospitalizations "very low." The agency reports only about four new COVID-19 hospital admissions per 100,000 people, a figure CNN notes is considered low. Influenza activity is also low and RSV, while moderate, is declining.
This juxtaposition, a new, potentially immune-evasive variant spreading locally against a backdrop of low overall disease activity, highlights the pandemic's shifting phase. The CDC no longer reports aggregate case counts, but continues to emphasize protective measures. Its guidance recommends universal masking in areas where more than 20 people per 100,000 are hospitalized with COVID-19 and that "high-risk" individuals should mask when between 10-19.9 people per 100,000 are hospitalized.
The agency underscores that variants with substantial immune evasion "could be associated with seasonal increases in COVID-19 activity" and that surveillance data will guide responses, including decisions around vaccine boosters, a topic that has drawn criticism from some who suggest the threat of new mandates is being used to push for additional doses.
The CDC report lists several limitations in its findings on BA.3.2, including variations in global reporting and the timing of sample collection. For now, the variant is not listed on the CDC's main variant tracker, which continues to be led by XFG lineages and XFY.
As the U.S. moves into spring of 2026, the message from health officials is one of watchful monitoring rather than alarm. The detection of BA.3.2 reinforces the virus's persistent evolution, but its ultimate trajectory and impact on a population with layered immunity remain the critical, unanswered questions guiding public health surveillance.
Watch this video about the weaknesses in the COVID data.
This video is from the Truth or Consequences channel on Brighteon.com.
Sources include:
Please contact us for more information.